Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone
- PMID: 18320710
- PMCID: PMC8110166
- DOI: 10.1111/j.1751-7176.2008.07917.x
Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone
Comment on
-
Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5. N Engl J Med. 2007. PMID: 17984165 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources